Excelsior Biopharma Inc Statistics
Excelsior Biopharma Inc (6496) Stock Statistics & Valuation Metrics
Total Valuation
Excelsior Biopharma Inc has a market cap or net worth of TWD 1.09B. The enterprise value is TWD 1.64B.
- Market Cap
- TWD 1.09B
- Enterprise Value
- TWD 1.64B
Share Statistics
Excelsior Biopharma Inc has 47,290,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 47,290,220
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Excelsior Biopharma Inc’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -12.96%.
- Return on Equity (ROE)
- -0.23
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -12.96%
- Return on Capital Employed (ROCE)
- -0.16
- Revenue Per Employee
- 59.88M
- Profits Per Employee
- -12.21M
- Employee Count
- 15
- Asset Turnover
- 0.61
- Inventory Turnover
- 1.89
Valuation Ratios
The current PE Ratio of Excelsior Biopharma Inc is -6.04. Excelsior Biopharma Inc’s PEG ratio is 0.48.
- PE Ratio
- -6.04
- PS Ratio
- 1.16
- PB Ratio
- 1.62
- Price to FCF
- -6.90
- Price to Operating Cash Flow
- -7.58
- PEG Ratio
- 0.48
Income Statement
In the last 12 months, Excelsior Biopharma Inc had revenue of 898.26M and earned -183.17M in profits. Earnings per share was -3.97.
- Revenue
- 898.26M
- Gross Profit
- 360.17M
- Operating Income
- -174.16M
- Pretax Income
- -172.34M
- Net Income
- -183.17M
- EBITDA
- -92.90M
- Earnings Per Share (EPS)
- -3.97
Cash Flow
In the last 12 months, operating cash flow was -147.42M and capital expenditures -14.60M, giving a free cash flow of -162.02M billion.
- Operating Cash Flow
- -147.42M
- Free Cash Flow
- -162.02M
- Free Cash Flow per Share
- -3.49
Dividends & Yields
Excelsior Biopharma Inc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.62%
- Earnings Yield
- -16.68%
Stock Price Statistics
- Beta
- 0.13
- 52-Week Price Change
- -20.10%
- 50-Day Moving Average
- 23.88
- 200-Day Moving Average
- 24.99
- Relative Strength Index (RSI)
- 40.67
- Average Volume (3m)
- 21.65K
Important Dates
Excelsior Biopharma Inc upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Excelsior Biopharma Inc as a current ratio of 1.95, with Debt / Equity ratio of 66.33%
- Current Ratio
- 1.95
- Quick Ratio
- 1.19
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- -3.75
- Interest Coverage Ratio
- -22.43
Taxes
In the past 12 months, Excelsior Biopharma Inc has paid 10.83M in taxes.
- Income Tax
- 10.83M
- Effective Tax Rate
- -0.06
Enterprise Valuation
Excelsior Biopharma Inc EV to EBITDA ratio is -11.99, with an EV/FCF ratio of -9.21.
- EV to Sales
- 1.55
- EV to EBITDA
- -11.99
- EV to Free Cash Flow
- -9.21
- EV to Operating Cash Flow
- -10.12
Balance Sheet
Excelsior Biopharma Inc has TWD 141.10M in cash and marketable securities with TWD 524.98M in debt, giving a net cash position of -TWD 383.88M billion.
- Cash & Marketable Securities
- TWD 141.10M
- Total Debt
- TWD 524.98M
- Net Cash
- -TWD 383.88M
- Net Cash Per Share
- -TWD 8.12
- Tangible Book Value Per Share
- TWD 14.77
Margins
Gross margin is 36.50%, with operating margin of -18.67%, and net profit margin of -19.24%.
- Gross Margin
- 36.50%
- Operating Margin
- -18.67%
- Pretax Margin
- -17.99%
- Net Profit Margin
- -19.24%
- EBITDA Margin
- -12.96%
- EBIT Margin
- -18.34%
Analyst Forecast
The average price target for Excelsior Biopharma Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 11.64%
- EPS Growth Forecast
- -10.83%
